Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells

A series of 36 pyrazol-4-yl pyridine derivatives (8a-i, 9a-i, 10a-i, and 11a-i) was designed, synthesized, and evaluated for its antiproliferative activity over NCI-60 cancer cell line panel and inhibitory effect against JNK isoforms (JNK1, JNK2, and JNK3). All the synthesized compounds were tested...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2023-12, Vol.261, p.115779-115779, Article 115779
Main Authors: Mersal, Karim I., Abdel-Maksoud, Mohammed S., Ali, Eslam M.H., Ammar, Usama M., Zaraei, Seyed-Omar, Haque, Md Mamunul, Das, Tanuza, Hassan, Noha F., Kim, Eunice EunKyeong, Lee, Jun-Seok, Park, HaJeung, Lee, Kwan Hyi, El-Gamal, Mohammed I., Kim, Hee-Kwon, Ibrahim, Tamer M., Oh, Chang-Hyun
Format: Article
Language:English
Subjects:
Arylsulfonamide
Cancer
JNK
Leukemia
Pyrazole
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A series of 36 pyrazol-4-yl pyridine derivatives (8a-i, 9a-i, 10a-i, and 11a-i) was designed, synthesized, and evaluated for its antiproliferative activity over NCI-60 cancer cell line panel and inhibitory effect against JNK isoforms (JNK1, JNK2, and JNK3). All the synthesized compounds were tested against the NCI-60 cancer cell line panel. Compounds 11b, 11c, 11g, and 11i were selected to determine their GI50s and exerted a superior potency over the reference standard SP600125 against the tested cell lines. 11c showed a GI50 of 1.28 μM against K562 leukemic cells. Vero cells were used to assess 11c cytotoxicity compared to the tested cancer cells. The target compounds were tested against hJNK isoforms in which compound 11e exhibited the highest potency against JNK isoforms with IC50 values of 1.81, 12.7, and 10.5 nM against JNK1, JNK2, and JNK3, respectively. Kinase profiling of 11e showed higher JNK selectivity in 50 kinase panels. Compounds 11c and 11e showed cell population arrest at the G2/M phase, induced early apoptosis, and slightly inhibited beclin-1 production at higher concentrations in K562 leukemia cells relative to SP600125. NanoBRET assay of 11e showed intracellular JNK1 inhibition with an IC50 of 2.81 μM. Also, it inhibited CYP2D6 and 3A4 with different extent and its hERG activity showed little cardiac toxicity with an IC50 of 4.82 μM. hJNK3 was used as a template to generate the hJNK1 crystal structure to explore the binding mode of 11e (PDB ID: 8ENJ) with a resolution of 2.8 °A and showed a typical type I kinase inhibition against hJNK1. Binding energy scores showed that selectivity of 11e towards JNK1 could be attributed to additional hydrophobic interactions relative to JNK3. [Display omitted] •Compounds 11c exhibited GI50 of 1.28 μM against NCI K562 cells.•Compound 11e showed some selectivity towards JNK1 with IC50 of 1.81 nM at 1 μM ATP and showed high JNK selectivity among 50 kinases.•11c and 11e exhibited G2/M phase arrest, early apoptosis and slight beclin-1 inhibition against K562 cells in comparison with SP600125.•11e inhibited JNK1 in HEK293 cells, CYP2A6, and CYP3A4 and showed little hERG activity.•11e showed type I kinase inhibition upon co-crystallization with JNK isoforms (PDB: 8ENJ).
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2023.115779